BaladoCritique : Club de lecture médical est une baladodiffusion (podcast) francophone mensuelle qui analyse et commente les études récentes d’impact majeur en médecine interne. Ces articles sont sélectionnés par un groupe d’experts en lecture critique de l’Université de Sherbrooke et de l’Université Laval en fonction du potentiel de changement de pratique en médecine familiale/médecine interne. Nous espérons que cet outil facilitera le transfert de nouvelles connaissances médicales aux professionnels de la santé et améliorera ainsi votre pratique médicale.
Épisode 78: Traitement intensif ciblant le cholestérol-LDL dans la maladie cardiovasculaire athérosclérotique (étude Ez-PAVE)
Diffusé le 19 mai 2026
Dans cette 78e baladodiffusion, les Drs Luc Lanthier et Pierre-Nicolas Perron discutent de traitement intensif de la dyslipidémie, en plus de réviser la littérature médicale d’avril 2026.
Quiz clinique (1 min51), présentation principale (2 min 23), critique (16 min 30), retour sur le cas clinique (22 min 25), autres articles (24 min 32), réponse au quiz clinique (27 min 32)
Lee YJ, Lee SJ, Kim JW, Lee SH, Kim GS, Park JH, et al; Ez-PAVE Investigators. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med. 2026;394(14):1365-1375. PubMed PMID: 41910315.
Probstfield JL, Branch KRH. Paving the Road toward Targeted Lipid Lowering. N Engl J Med. 2026 Apr 9;394(14):1443-1444. PubMed PMID: 41910324.
Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. PubMed PMID: 40878289.
Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al; VESALIUS-CV Investigators. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026;335(16):1400-1407. PubMed PMID: 41903215.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. PubMed PMID: 15007110.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. PubMed PMID: 15755765.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. PubMed PMID: 26039521.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. PubMed PMID: 28304224.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. PubMed PMID: 30403574.
Landmesser U, Skurk C, Kirchhof P, Lewalter T, Hartung J, Rroku A, et al; CLOSURE-AF Trial Investigators. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. N Engl J Med. 2026;394(13):1270-1280. PubMed PMID: 41849741.
Choi KH, Kang D, Kim W, Doh JH, Kim J, Park YH, et al; SMART-DECISION Investigators. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. N Engl J Med. 2026;394(13):1302-1312. PubMed PMID: 41910427.
Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, et al; OCEANIC-STROKE Investigators. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026;394(15):1467-1479. PubMed PMID: 41985132.
Butler CC, Pinto AD, Harris V, Holmes J, Rahman NM, Cureton L, et al; PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. N Engl J Med. 2026;394(16):1583-1594. PubMed PMID: 42019019.
Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026;54(4):725-812. PubMed PMID: 41869847.
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PubMed PMID: 41824552.
Öberg J, Buchwald P, Nilsson A, Nilson B, Inghammar M. Risk and prognosis of colorectal cancer following bacteraemia with Streptococcus bovis-Streptococcus equinus complex: A Swedish nationwide retrospective cohort study. Epidemiol Infect. 2025;154:e2. PubMed PMID: 41449806.
Abdulamir AS, Hafidh RR, Abu Bakar F. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res. 2011;30(1):11. PubMed PMID: 21247505.
Les BaladoCritiques sont offertes en collaboration avec le Centre de formation continue (CFC) de la Faculté de Médecine et des sciences de la santé de l'Université de Sherbrooke. Pour connaître toutes les offres de formation du CFC, cliquez ici.
